Welcome to our dedicated page for BRII BIOSCIENCES news (Ticker: BRIBY), a resource for investors and traders seeking the latest updates and insights on BRII BIOSCIENCES stock.
Brii Biosciences Limited (BRIBY) delivers innovative therapies targeting chronic hepatitis B and infectious diseases through advanced biotherapeutic platforms. This news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory progress.
Access authoritative reporting on key initiatives including HBV combination therapies, siRNA advancements, and global clinical trial updates. Our curated news collection ensures you stay informed about BRII-877, BRII-835, and other pipeline candidates without promotional bias.
Discover verified updates across essential categories: clinical trial results, regulatory submissions, research collaborations, and therapy development milestones. Each update is vetted for relevance to long-term therapeutic goals and shareholder value.
Bookmark this page for streamlined access to Brii Biosciences' latest advancements in functional cure research. Check regularly for objective reporting on innovations shaping the future of HBV treatment.
Brii Biosciences Limited reported its fiscal year 2022 results, highlighting a revenue increase to RMB51.6 million due to the COVID-19 therapy commercialization in China. The company is focused on advancing its clinical programs for hepatitis B and depression, with Phase 2 trials set for 2023. Financially, R&D expenses decreased by 10.9% to RMB440.6 million, while total comprehensive expense fell by 94.4% to RMB238.5 million. Brii Bio discontinued its COVID-19 antibody program to prioritize its main clinical projects and remains well-funded through 2025.
Brii Biosciences announced significant clinical development updates, focusing on two lead programs for hepatitis B and postpartum depression. The company completed patient enrollment in Phase 2 trials for both areas, revealing promising preliminary results. Notably, the U.S. FDA lifted the clinical hold on BRII-732, allowing a restart of trials for a potential HIV treatment. While the company aims to address high unmet medical needs, it also plans to explore partnerships for its discontinued HIV candidate, BRII-778.
Brii Biosciences announced promising results from two Phase 1 studies evaluating BRII-732 and BRII-778 for HIV treatment. Both candidates showed safety and tolerability, suggesting potential for a once-weekly oral combination therapy. Data presented at IDWeek 2022 highlighted their favorable pharmacokinetic profiles, which may enhance adherence compared to daily regimens. Brii aims to advance these compounds through clinical development, addressing the needs of over 38 million people living with HIV globally.
Brii Biosciences announced the top-line results from its Phase 1 study of BRII-296, a long-acting, single-injection therapy for postpartum depression (PPD). The 600 mg dosage was shown to be safe and well-tolerated, with a favorable pharmacokinetic profile. These findings position BRII-296 as a potential one-time outpatient treatment for PPD, addressing the needs of the 900,000 individuals affected in the U.S. annually. The company plans to move forward with a Phase 2 clinical trial by the end of 2022, focusing on patient-centered development.
